Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aura Biosciences, Inc.AURA · Entity 5142 | Director · See Remarks | May 19, 2026 | May 19, 2026 |
| LeonaBio, Inc.LONA · Entity 1487 | Director | June 23, 2026 | June 24, 2026 |
| Rubius Therapeutics, Inc.RUBY · Entity 116417 | Director | May 12, 2022 | May 13, 2022 |
| Third Harmonic Bio, Inc.THRD · Entity 76517 | Director · CEO | August 11, 2025 | August 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aura Biosciences, Inc.
Report date May 19, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,153,962 |
Ending reported balance
After 2026-05-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-19 · Grant · Acquired 600,118 · Balance 600,118 F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award as Inducement Awards. Each RSU represents the right to receive one share of the Issuer's common stock. These RSUs vest in four substantially equal annual installments beginning on April 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. Row 2 · 2026-05-19 · Grant · Acquired 553,844 · Balance 1,153,962 F2: These shares were acquired pursuant to a performance RSU ("PRSU") award as Inducement Awards. The PRSUs are subject to both time-based vesting and the achievement of a performance condition, both of which must be satisfied before the PRSUs will be deemed vested. The PRSUs shall vest in four substantially equal annual installments commencing on April 15, 2027, subject to Ms. Holles' continued service as of each such time-based vesting date and the satisfaction of the performance condition. The expiration date of the PRSUs is the earlier of (i) the sixth (6th) anniversary of the grant date and (ii) the date Ms. Holles no longer has a service relationship with the Issuer. Any such PRSUs that have not vested on or prior to such expiration date shall be forfeited for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.39 · Expires 2036-05-19 | Direct | 2,169,103 |
Reported balance
After 2026-05-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-19 · Grant · Acquired 2,169,103 · Balance 2,169,103 F3: The shares underlying this option vest as follows: 25% of the shares vest on April 30, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award as Inducement Awards. Each RSU represents the right to receive one share of the Issuer's common stock. These RSUs vest in four substantially equal annual installments beginning on April 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.
F2: These shares were acquired pursuant to a performance RSU ("PRSU") award as Inducement Awards. The PRSUs are subject to both time-based vesting and the achievement of a performance condition, both of which must be satisfied before the PRSUs will be deemed vested. The PRSUs shall vest in four substantially equal annual installments commencing on April 15, 2027, subject to Ms. Holles' continued service as of each such time-based vesting date and the satisfaction of the performance condition. The expiration date of the PRSUs is the earlier of (i) the sixth (6th) anniversary of the grant date and (ii) the date Ms. Holles no longer has a service relationship with the Issuer. Any such PRSUs that have not vested on or prior to such expiration date shall be forfeited for no consideration.
F3: The shares underlying this option vest as follows: 25% of the shares vest on April 30, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.
LeonaBio, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.35 · Expires 2036-06-22 | Direct | 2,333 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 2,333 · Balance 2,333 F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy and is pro-rated based on the reporting person's appointment to the Issuer's board of directors on May 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy and is pro-rated based on the reporting person's appointment to the Issuer's board of directors on May 5, 2026.
Rubius Therapeutics, Inc.
Report date May 12, 2022 · Filed May 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2032-05-11 | Direct | 25,000 |
Reported balance
After 2022-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-12 · Grant · Acquired 25,000 · Balance 25,000 F1: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service.
Third Harmonic Bio, Inc.
Report date August 11, 2025 · Filed August 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-08-11 transaction · row 1
1 source rowRow 1 · 2025-08-11 · Other · Disposed 1,218,836 · Balance 0 F1: Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer. F2: The reporting person received a liquidation distribution of $5.35 per share of Common Stock from Issuer. |
| Stock OptionSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-08-11 · Other · Disposed 998,854 · Balance 0 F3: Represents payment of the liquidation distribution of $5.35 per share less the exercise price of such options. F1: Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-08-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-08-11 · Other · Disposed 50,000 · Balance 0 F4: The restricted stock units were deemed vested aod settled on the date of the liquidation distribution, and such settled shares received a liquidation distribution of $5.35 per share. F1: Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer.
F2: The reporting person received a liquidation distribution of $5.35 per share of Common Stock from Issuer.
F3: Represents payment of the liquidation distribution of $5.35 per share less the exercise price of such options.
F4: The restricted stock units were deemed vested aod settled on the date of the liquidation distribution, and such settled shares received a liquidation distribution of $5.35 per share.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Allakos Inc.
Report date May 25, 2021 · Filed October 14, 2021
Section 16 reporting ended · disclosed 2021-10-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.83 · Expires 2031-05-25 | Direct | 7,700 |
Reported balance
After 2021-05-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-25 · Grant · Acquired 7,700 · Balance 7,700 F1: The option vests as to 100% of the shares on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next Annual Meeting that occurs following the grant, subject to the Reporting Person continuing as a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 100% of the shares on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next Annual Meeting that occurs following the grant, subject to the Reporting Person continuing as a service provider through each such date.
Audentes Therapeutics, Inc.
Report date January 15, 2020 · Filed January 15, 2020
Section 16 reporting ended · disclosed 2020-01-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 1
1 source rowRow 1 · 2020-01-15 · Other · Disposed 104,439 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.76 · Expires 2025-11-06 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-15 · Disposition to issuer · Disposed 110,703 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2025-12-18 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-15 · Disposition to issuer · Disposed 548 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.26 · Expires 2027-01-25 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-15 · Disposition to issuer · Disposed 40,883 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.39 · Expires 2027-11-16 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-01-15 · Disposition to issuer · Disposed 93,109 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.39 · Expires 2028-05-07 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-01-15 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.74 · Expires 2029-02-06 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-01-15 · Disposition to issuer · Disposed 50,105 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price.
F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Day One Biopharmaceuticals, Inc.
Report date April 23, 2026 · Filed April 23, 2026
Section 16 reporting ended · disclosed 2026-04-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 1
1 source rowRow 1 · 2026-04-23 · Disposition to issuer · Disposed 57,310 · Balance 0 F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2031-05-25 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-23 · Disposition to issuer · Disposed 40,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2031-05-25 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-23 · Disposition to issuer · Disposed 40,300 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2032-06-20 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-23 · Disposition to issuer · Disposed 28,700 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2033-06-21 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-23 · Disposition to issuer · Disposed 37,500 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2034-05-22 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-23 · Disposition to issuer · Disposed 32,335 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2035-06-01 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-23 · Disposition to issuer · Disposed 22,500 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F5: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-23 · Disposition to issuer · Disposed 15,000 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F7: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each RSU Vesting Date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F8: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.
F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.
F3: The options are fully vested.
F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes.
F5: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date.
F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F7: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each RSU Vesting Date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.
F8: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2021 Filed Jan 6, 2021 17:32 UTC | Allakos Inc. ALLK · Entity 79644 | GrantStock Option (Right to buy) · Derivative | 4,000 | $0.00 Strike: $133.77 | $0.00 |
DisclosureSEC source: 0001209191-21-002275 · doc4.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2031-01-04 F1 · derivative.exercise_date: The option vests as to one thirty-sixth of the shares on January 21, 2021 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 21, 2020 Filed May 26, 2020 20:52 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001179110-20-006611 · edgar.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. Read SEC document |
| January 15, 2020 Filed Jan 15, 2020 13:29 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,105 | Not disclosed Strike: $24.74 | Not disclosed |
DisclosureSEC source: 0001209191-20-003428 · doc4.xml · derivative · entry 7 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,105 shares Expires 2029-02-06 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 15, 2020 Filed Jan 15, 2020 13:29 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $36.39 | Not disclosed |
DisclosureSEC source: 0001209191-20-003428 · doc4.xml · derivative · entry 6 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2028-05-07 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 15, 2020 Filed Jan 15, 2020 13:29 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Disposition to issuerStock Option (Right to Buy) · Derivative | 93,109 | Not disclosed Strike: $27.39 | Not disclosed |
DisclosureSEC source: 0001209191-20-003428 · doc4.xml · derivative · entry 5 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 93,109 shares Expires 2027-11-16 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 15, 2020 Filed Jan 15, 2020 13:29 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Disposition to issuerStock Option (Right to Buy) · Derivative | 40,883 | Not disclosed Strike: $15.26 | Not disclosed |
DisclosureSEC source: 0001209191-20-003428 · doc4.xml · derivative · entry 4 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,883 shares Expires 2027-01-25 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 15, 2020 Filed Jan 15, 2020 13:29 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Disposition to issuerStock Option (Right to Buy) · Derivative | 548 | Not disclosed Strike: $9.50 | Not disclosed |
DisclosureSEC source: 0001209191-20-003428 · doc4.xml · derivative · entry 3 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 548 shares Expires 2025-12-18 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 15, 2020 Filed Jan 15, 2020 13:29 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Disposition to issuerStock Option (Right to Buy) · Derivative | 110,703 | Not disclosed Strike: $2.76 | Not disclosed |
DisclosureSEC source: 0001209191-20-003428 · doc4.xml · derivative · entry 2 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,703 shares Expires 2025-11-06 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 15, 2020 Filed Jan 15, 2020 13:29 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | OtherCommon Stock | 104,439 | $60.00 | $6,266,340.00 |
DisclosureSEC source: 0001209191-20-003428 · doc4.xml · nonDerivative · entry 1 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 18:03 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 14,895 | $0.00 Strike: $24.74 | $0.00 |
DisclosureSEC source: 0001209191-19-060728 · doc4.xml · derivative · entry 12 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,105 Underlying: Common Stock · 14,895 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning February 1, 2019, with 100% of the total shares vested and exercisable on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 18:03 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 6,891 | $0.00 Strike: $27.39 | $0.00 |
DisclosureSEC source: 0001209191-19-060728 · doc4.xml · derivative · entry 11 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,109 Underlying: Common Stock · 6,891 shares Expires 2027-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning December 16, 2017, with 100% of the total shares vested and exercisable on November 16, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 18:03 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 74,117 | $0.00 Strike: $15.26 | $0.00 |
DisclosureSEC source: 0001209191-19-060728 · doc4.xml · derivative · entry 10 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,883 Underlying: Common Stock · 74,117 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning February 25, 2017, with 100% of the total shares vested and exercisable on January 25, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 18:03 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 5,715 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0001209191-19-060728 · doc4.xml · derivative · entry 9 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 548 Underlying: Common Stock · 5,715 shares Expires 2025-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests as to 6.25% of the total shares quarterly, beginning March 18, 2016, with 100% of the total shares vested and exercisable on December 18, 2019, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting upon the occurrence of certain events. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 18:03 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 45,726 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001209191-19-060728 · doc4.xml · derivative · entry 8 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,703 Underlying: Common Stock · 45,726 shares Expires 2025-11-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests as to 25% of the total shares on August 17, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on August 17, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 18:03 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Tax withholdingCommon Stock | 88,928 | $59.37 | $5,279,655.36 |
DisclosureSEC source: 0001209191-19-060728 · doc4.xml · nonDerivative · entry 7 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,439 F3 · kind: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the exercise of stock options. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 18:03 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 14,895 | $24.74 | $368,502.30 |
DisclosureSEC source: 0001209191-19-060728 · doc4.xml · nonDerivative · entry 6 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 18:03 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon stock | 6,891 | $27.39 | $188,744.49 |
DisclosureSEC source: 0001209191-19-060728 · doc4.xml · nonDerivative · entry 5 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 18:03 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 74,117 | $15.26 | $1,131,025.42 |
DisclosureSEC source: 0001209191-19-060728 · doc4.xml · nonDerivative · entry 4 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 18:03 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 5,715 | $9.50 | $54,285.64 |
DisclosureSEC source: 0001209191-19-060728 · doc4.xml · nonDerivative · entry 3 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 18:03 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 45,726 | $2.76 | $126,427.82 |
DisclosureSEC source: 0001209191-19-060728 · doc4.xml · nonDerivative · entry 2 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 18:03 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Tax withholdingCommon Stock | 8,681 | $59.37 | $515,390.97 |
DisclosureSEC source: 0001209191-19-060728 · doc4.xml · nonDerivative · entry 1 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,023 F1 · security: On December 10, 2019, the Compensation Committee of the Issuer's Board of Directors approved the accelerated vesting and settlement of restricted stock units granted on February 6, 2019 in order to mitigate the potential adverse tax consequences of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended. F2 · kind: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 17:15 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Tax withholdingCommon Stock | 505 | $59.21 | $29,901.05 |
DisclosureSEC source: 0001209191-19-059739 · doc4.xml · nonDerivative · entry 1 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,704 F1 · kind: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 16:04 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Tax withholdingCommon Stock | 505 | $31.02 | $15,665.10 |
DisclosureSEC source: 0001209191-19-048876 · doc4.xml · nonDerivative · entry 1 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,209 F1 · kind: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 16:41 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Tax withholdingCommon Stock | 1,009 | $37.31 | $37,645.79 |
DisclosureSEC source: 0001209191-19-035584 · doc4.xml · nonDerivative · entry 1 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,714 F1 · kind: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. Read SEC document |
| March 29, 2019 Filed Apr 1, 2019 18:01 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $18.10 | $0.00 |
DisclosureSEC source: 0001104659-19-019036 · a4.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-03-28 F1 · derivative.exercise_date: This option shall vest in equal quarterly installments over the twelve quarters following the grant date. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 17:20 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $24.74 | $0.00 |
DisclosureSEC source: 0001209191-19-008664 · doc4.xml · derivative · entry 2 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-02-06 F2 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning February 1, 2019, with 100% of the total shares vested and exercisable on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 17:20 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | GrantCommon Stock | 23,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008664 · doc4.xml · nonDerivative · entry 1 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,723 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock upon settlement for no consideration. The RSUs will vest as to 2/16ths of the award on June 5, 2019, and then 1/16th of the RSUs will vest on each of September 5, December 5, March 5 and June 5 thereafter until the RSUs are fully vested, subject to the Reporting Person's provision of services to the issuer on each vesting date. Shares of the issuer's Common Stock will be delivered to the Reporting Person following vesting. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 19:28 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 8,300 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001209191-19-005437 · doc4.xml · derivative · entry 2 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,429 Underlying: Common Stock · 8,300 shares Expires 2025-11-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests as to 25% of the total shares on August 17, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on August 17, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 19:28 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 8,300 | $2.76 | $22,948.67 |
DisclosureSEC source: 0001209191-19-005437 · doc4.xml · nonDerivative · entry 1 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,390 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares acquired in connection with the exercise of stock options described in Table II. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 16:48 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 5,090 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001209191-18-035174 · doc4.xml · derivative · entry 2 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,729 Underlying: Common Stock · 5,090 shares Expires 2025-11-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests as to 25% of the total shares on August 17, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on August 17, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 16:48 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 5,090 | $2.76 | $14,073.34 |
DisclosureSEC source: 0001209191-18-035174 · doc4.xml · nonDerivative · entry 1 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares acquired in connection with the exercise of stock options described in Table II. Read SEC document |
| May 07, 2018 Filed May 8, 2018 08:08 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $36.39 | $0.00 |
DisclosureSEC source: 0001209191-18-028492 · doc4.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-05-07 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning June 2, 2018, with 100% of the total shares vested and exercisable on May 2, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 17:04 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $27.39 | $0.00 |
DisclosureSEC source: 0001209191-17-061538 · doc4.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Senior Vice President, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-11-16 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning December 16, 2017, with 100% of the total shares vested and exercisable on November 16, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| May 31, 2017 Filed Jun 1, 2017 16:31 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001209191-17-036792 · doc4.xml · derivative · entry 2 Holles Natalie C. · CIK 0001580111 · Senior Vice President, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,819 Underlying: Common Stock · 20,000 shares Expires 2025-11-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests as to 25% of the total shares on August 17, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on August 17, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| May 31, 2017 Filed Jun 1, 2017 16:31 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 20,000 | $2.76 | $55,200.00 |
DisclosureSEC source: 0001209191-17-036792 · doc4.xml · nonDerivative · entry 1 Holles Natalie C. · CIK 0001580111 · Senior Vice President, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares acquired in connection with the exercise of stock options described in Table II. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 18:06 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | GrantStock Option (right to buy) · Derivative | 115,000 | $0.00 Strike: $15.26 | $0.00 |
DisclosureSEC source: 0001209191-17-005995 · doc4.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Senior Vice President, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2027-01-25 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning February 25, 2017, with 100% of the total shares vested and exercisable on January 25, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.